Results 151 to 160 of about 204,688 (384)

Model‐Informed Precision Dosing of Infliximab in Korean Inflammatory Bowel Disease Patients: External Validation of Population Pharmacokinetic Models

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Underexposure to infliximab often leads to loss of response in patients with inflammatory bowel disease (IBD). Model‐informed precision dosing (MIPD) offers a superior approach to maintaining target infliximab concentrations compared to empirical dosage adjustment.
Yoonjin Kim, Seung Hwan Baek, In‐Jin Jang, Jae‐Yong Chung   +3 more
wiley   +1 more source

INFLUENCE OF ERYTHROMYCIN ON CYCLOSPORINE PHARMACOKINETICS

, 1987
P Vereerstraeten, Philippe Thiry, P Kinnaert, C Toussaint   +3 more
openalex   +1 more source

Disease Modification of Pustular Psoriasis by Secukinumab: A 20‐Year Follow‐Up of Von Zumbusch‐Type Generalized Pustular Psoriasis With Evolution Into Annular Pustular Psoriasis—A Case Report

The Kaohsiung Journal of Medical Sciences, EarlyView.
Yu‐Han Alice Hsu, Cheng‐Che E. Lan, Sheng‐Yiao Lin   +2 more
wiley   +1 more source

Rosuvastatin PBPK Modeling: Incorporating Liver Concentrations and Effects of Ethnicity, Genetic Polymorphisms, Lactone Formation, DDI and Pregnancy

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Rosuvastatin (RSV), a potent HMG‐CoA reductase inhibitor, is widely used for the management of hyperlipidemia and prevention of cardiovascular disease. Its absorption and disposition are primarily transporter‐mediated, involving intestinal absorption by OATP2B1 and efflux by BCRP; hepatic uptake by OATP1B1, OATP1B3, OATP2B1, and NTCP; and ...
Ankit Balhara, Robert H. Weber, Jashvant D. Unadkat   +2 more
wiley   +1 more source

Cadaveric Renal transplantation with Cyclosporine: Experiences in 148 patients at a single institution. [PDF]

, 1983
Castro, L. A., Günther, K., Hammer, C., Hillebrand, Günther, Illner, Wolf-Dieter, Land, Walter, Schmeller, N., Schneider, B., Siebert, W., Zink, R., Zöttlein, H.   +10 more
core   +1 more source

Effect of cyclosporine on reperfusion injury in acute myocardial infarction.

New England Journal of Medicine, 2008
C. Piot, P. Croisille, P. Staat, H. Thibault, G. Rioufol, N. Mewton, R. Elbelghiti, T. Cung, E. Bonnefoy, D. Angoulvant, C. Macía, F. Raczka, C. Sportouch, G. Gahide, G. Finet, X. André‐Fouët, D. Revel, G. Kirkorian, J. Monassier, G. Derumeaux, M. Ovize   +20 more
semanticscholar   +1 more source

Model‐Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Model‐informed drug development (MIDD) has been increasingly applied to guide decision‐making, ameliorate efficiency, and enhance the likelihood of successful trials. The development of ligelizumab, a humanized anti‐IgE monoclonal antibody, in chronic spontaneous urticaria (CSU) illustrated how MIDD can be applied to support central aspects of
Andrzej Bienczak, Aurelie Gautier, Eva Hua, Yan Ji, Emil Scosyrev, Serge Smeets, Thomas Severin, Anton Drollmann, Manmath Patekar, Marina Savelieva   +9 more
wiley   +1 more source

Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies [PDF]

, 2000
Acquired hemophilia, caused by autoantibodies against coagulation factor VIII, is usually treated with steroids, cyclophosphamide, intravenous gammaglobulins and sporadically other drugs.
Baele, Gaston, Derom, Eric, Petrovic, Mirko   +2 more
core  

LONG-TERM NORMOGLYCEMIA IN PANCREATECTOMIZED DOGS FOLLOWING PANCREATIC ISLET ALLOTRANSPLANTATION AND CYCLOSPORINE IMMUNOSUPPRESSIONxs

, 1987
Norman M. Kneteman, Derek Alderson, David W. Scharp   +2 more
openalex   +1 more source

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki, Ryo Saito, Kenta Suzuki, Daisuke Watanabe, Masako Minami‐Hori, Hirofumi Kamada, Hiroo Amano, Akihiko Uchiyama, Sei‐ichiro Motegi, Machiko Kamura, Kazunari Sugita, Noriko Kubota, Toshifumi Nomura, Maki Ozawa, Toshiya Takahashi, Takashi Yamakita, Kazumitsu Sugiura, Tetsuharu Ikegami, Ken Igawa, Yuka Kimura, Yoko Kataoka, Ryoichi Kamide, Masakazu Takahashi, Akio Tanaka, Mariko Sugawara‐Mikami   +24 more
wiley   +1 more source